about
AHR over-expression in papillary thyroid carcinoma: clinical and molecular assessments in a series of Italian acromegalic patients with a long-term follow-up.A novel mutation in the upstream open reading frame of the CDKN1B gene causes a MEN4 phenotype.A constitutive active MAPK/ERK pathway due to BRAFV600E positively regulates AHR pathway in PTC.The GIP/GIPR axis is functionally linked to GH-secretion increase in a significant proportion of gsp- somatotropinomas.Activation of the dopamine receptor type-2 (DRD2) promoter by 9-cis retinoic acid in a cellular model of Cushing's disease mediates the inhibition of cell proliferation and ACTH secretion without a complete corticotroph-to-melanotroph transdifferentInvestigation of N-cadherin/β-catenin expression in adrenocortical tumors.Diagnostic accuracy of increased urinary cortisol/cortisone ratio to differentiate ACTH-dependent Cushing's syndrome.First-line screening tests for Cushing's syndrome in patients with adrenal incidentaloma: the role of urinary free cortisol measured by LC-MS/MS.The (193-209) 17-residues peptide of bovine β-casein is transported through Caco-2 monolayer.Different therapeutic options in patients with Cushing's syndrome due to bilateral macronodular adrenal hyperplasia.Early recognition of aggressive pituitary adenomas: a single-centre experience.Large Genomic Rearrangements of Desmosomal Genes in Italian Arrhythmogenic Cardiomyopathy Patients.Daily salivary cortisol and cortisone rhythm in patients with adrenal incidentaloma.Acromegaly Is More Severe in Patients With AHR or AIP Gene Variants Living in Highly Polluted Areas.Paradoxical GH increase during OGTT is associated to first-generation somatostatin analogs responsiveness in acromegalyA multicenter experience on the prevalence of ARMC5 mutations in patients with primary bilateral macronodular adrenal hyperplasia: from genetic characterization to clinical phenotypeThe pathogenic role of the GIP/GIPR axis in human endocrine tumors: emerging clinical mechanisms beyond diabetes
P50
Q33895577-D9A92725-B1D7-4693-AB10-8B09FFA17A13Q34649802-C379779C-F98D-4C56-9308-36E07DE20C11Q36544784-CFD9EBFC-0A3F-40D7-B34A-AF228A4E5D48Q38717209-37DF36D8-4246-4C30-885D-3735ABC3BE8FQ38985205-ACCED46F-5C48-4E70-90DC-B6FBFE32523BQ39549740-CE9020A2-0BD8-404D-BB32-20958A64DB21Q40169381-431A2817-5F9A-4668-A550-464CC27BE20EQ40313813-634312CC-FD68-4F23-8C38-DC904725AE33Q43097001-98F565D2-CA12-4626-840A-74E225B2D5F6Q47438722-9A4B94EC-9A94-4A7F-980C-6C35CF360C7DQ47573398-7F48D93B-32B9-4F78-BE7C-F847A9DC31E2Q47644282-271465E1-3133-4E65-B61A-B6607337438DQ48278106-D20BD7FA-AA7E-48CC-BE0A-EEDEC948D502Q53793757-DE441AD1-6779-49C0-8612-2E47C46E72A9Q57037753-D44D911B-2640-483A-B148-E20AF8393B82Q89256648-7BD91C0C-8E67-4CC6-B9B5-AAFD1936D350Q92613514-C39519B2-7EA9-465F-B04C-323BBC720D47
P50
description
investigador
@es
researcher
@en
name
Daniela Regazzo
@en
type
label
Daniela Regazzo
@en
prefLabel
Daniela Regazzo
@en
P31
P496
0000-0002-1942-7202